Assessment of the Long-term Safety and Efficacy of Erenumab During Open-label Treatment in Patients With Chronic Migraine

Stewart J. Tepper,1 Messoud Ashina,2 Uwe Reuter,3 Jan L. Brandes,4 David Doležil,5 Stephen Silberstein,6 Paul Winner,7 Feng Zhang,8 Sunfa Cheng,9 Daniel D. Mikol9

References  | Acknowledgements  | Disclosures 

References

  1. Aimovig® (erenumab-aooe) Prescribing Information, 2019.
  2. Tepper S, et al. Lancet Neurol. 2017;16:425-34.

Acknowledgments

The authors acknowledge the following Novartis employees for development of the original poster: Sashi Kiran Goteti for medical writing assistance and coordinating author reviews, and Durgam Anand for design assistance. The final responsibility of the content lies with the authors.

Disclosures

The study was supported by Amgen and Novartis. Erenumab is co-developed by Amgen and Novartis. Stewart J. Tepper – Employee of the Cleveland Clinic during this study; research grants (no personal compensation) from Allergan, Amgen, ATI, Avanir, ElectroCore, eNeura, Teva, and Zosano; consultant fees from Acorda, Allergan, Amgen, ATI, Avanir, Depomed, electroCore, eNeura, Impax, Kimberly Clark, Pfizer, Scion Neurostim, Teva, and Zosano; speakers’ bureau (2015 only) for Allergan, Depomed, Impax, Pernix, and Teva; advisory board for Alder, Allergan, Amgen, ATI, Acorda, Dr. Reddy’s, Kimberly Clark, Teva, Pfizer, and Zosano; stock options from ATI; salary from American Headache Society; royalties from University of Mississippi Press and Springer. Messoud Ashina – Consultant or scientific advisor for Allergan, Amgen, Alder, ATI, Novartis, and Eli Lilly; primary investigator for Amgen, and GM-11 gamma-Core-R trials; grants from Lundbeck Foundation, Research Foundation of the Capital Region of Copenhagen, Danish Council for Independent Research-Medical Sciences and Novo Nordisk Foundation. Uwe Reuter – Consulting fees, speaking/teaching fees, and/or research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, Novartis, and Pharm Allergan. Jan L. Brandes – Consulting fees, speaking fees, and/or research grants from Allergan, Amgen, Avanir, Depomed, Clinvest, Daiichi Sankyo, Pernix, Merck, Supernus, Teva, Arteaus, and Eli Lilly. David Doležil – Consulting fees and speaking and/or teaching fees from Allergan, Amgen, Biogen Idec, Novartis, Bayer, and Teva. Stephen Silberstein – Consultant and/or advisory panel member for and/or honoraria from Alder, Allergan, Amgen, Avanir, Dr. Reddy’s, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe Pharma America, NINDS, Supernus, Trigemina, and Teva. Paul Winner – Consulting fees/honoraria from Allergan, Amgen, Lilly, Teva, and Supernus; speakers’ bureau for Allergan, Amgen, Avanir, Teva and Supernus; research grants from Allergan, Amgen, NuPathe, AstraZeneca, Avanir, Eli Lilly, Novartis and Teva. Feng Zhang, Sunfa Cheng, Daniel D. Mikol – Employees of and stockholders in Amgen.

1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Nashville Neuroscience Group and Vanderbilt University Department of Neurology, Nashville, TN, USA; 5Dado Medical sro, Prague Headache Center, Prague, Czech Republic; 6Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 7Premiere Research Institute, Nova Southeastern University, West Palm Beach, FL, USA; 8Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA; 9Global Development, Amgen Inc., Thousand Oaks, CA, USA.